A clinical trial to study the effect of a drug, curcumin in patients with periodontitis

INTERVENTION: Intervention1: 1% curcumin chip in biodegradable hydroxy propyl methyl cellulose vehicle: Following routine full mouth scaling and root planing within 48 hours, a single 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement) Control Intervention1: Placebo chips in biodegradable hydroxy propyl methyl cellulose vehicle: Following routine full mouth scaling and root planing within 48 hours, a single 4x5x0.5mm placebo chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement) CONDITION: Chronic periodontitis PRIMARY OUTCOME: Levels of interleukin 1 beta in the gingival crevicular fluid quantified by ELISA in picogram per milliliterTimepoint: 1 month from baseline SECONDARY OUTCOME: Probing pocket depth ; Clinical attachment level ; Gingival index by Loe and Silness in 1963 ; Plaque index by Silness and Loe in 1964 ; Timepoint: 1 month and 3 months from baseline INCLUSION CRITERIA: 1 Systemically healthy individuals 2 Presence of a minimum of 20 teeth in the oral cavity 3 Localised periodontal pockets with probing depths greater than 4mm i.e., Periodontitis in its stages 2 and 3, as described by the 2017 World Workshop on the Classification of Periodontal and Peri‐Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP)